ExodusPoint Capital Management LP Purchases Shares of 11,079 Zymeworks Inc. (NYSE:ZYME)

ExodusPoint Capital Management LP purchased a new stake in shares of Zymeworks Inc. (NYSE:ZYME – Get Rating) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 11,079 shares of the company’s stock, valued at approximately $68,000.

Other hedge funds have also bought and sold shares of the company. Quantbot Technologies LP purchased a new position in shares of Zymeworks in the first quarter valued at about $42,000. Envestnet Asset Management Inc. purchased a new position in shares of Zymeworks in the second quarter valued at about $62,000. First Republic Investment Management Inc. purchased a new position in shares of Zymeworks in the first quarter valued at about $66,000. Lazard Asset Management LLC purchased a new position in shares of Zymeworks in the first quarter valued at about $66,000. Finally, Virtu Financial LLC purchased a new position in shares of Zymeworks in the second quarter valued at about $70,000. Institutional investors own 88.28% of the company’s stock.

Zymeworks Stock Up 0.1 %

Shares of NYSE:ZYME opened at $8.01 on Monday. Zymeworks Inc. has a 52-week low of $4.11 and a 52-week high of $10.80. The stock has a market cap of $504.63 million, a P/E ratio of -2.09 and a beta of 0.91. The business’s 50 day moving average is $8.78 and its 200 day moving average is $7.37.

Analyst Ratings Changes

Several equities analysts have recently commented on ZYME shares. HC Wainwright restated a “neutral” rating and issued a $8.00 price objective on shares of Zymeworks in a research report on Tuesday, January 24th. Jefferies Financial Group upgraded Zymeworks from a “hold” rating to a “buy” rating and boosted their target price for the stock from $7.70 to $11.00 in a research report on Monday, December 19th. Guggenheim boosted their target price on Zymeworks from $15.00 to $16.00 in a research report on Thursday, January 19th. Barclays boosted their target price on Zymeworks from $7.00 to $9.00 and gave the stock an “equal weight” rating in a research report on Thursday, December 22nd. Finally, SVB Leerink upped their price objective on Zymeworks from $8.00 to $10.00 and gave the company a “market perform” rating in a research report on Friday, January 20th. Three investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $13.00.

Insider Buying and Selling

In other news, major shareholder Ecor1 Capital, Llc acquired 342,100 shares of the company’s stock in a transaction that occurred on Friday, January 13th. The shares were bought at an average price of $9.81 per share, with a total value of $3,356,001.00. Following the completion of the purchase, the insider now directly owns 8,936,973 shares in the company, valued at $87,671,705.13. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders have bought a total of 1,846,200 shares of company stock valued at $16,073,510 over the last quarter. 1.63% of the stock is owned by corporate insiders.

Zymeworks Company Profile

(Get Rating)

Zymeworks Inc is a biopharmaceutical company. It engages in the discovery, development, and commercialization of multifunctional biotherapeutics, initially focused on the treatment of cancer. The company is headquartered in Middletown, DE.